Furthermore, a phase I trial in 44 patients with recurrent GBM is currently ongoing and is exploring the therapeutic effectiveness of targeting the checkpoint molecules anti-LAG-3 (lymphocyte activation gene) or anti-CD137 alone and in combination with anti-PD-1 (phase I trial, NCT02658981). This evidence concerns the gene PDCD1 and glioblastoma.